US Bancorp DE Boosts Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

US Bancorp DE grew its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 346.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,943 shares of the company’s stock after acquiring an additional 1,508 shares during the quarter. US Bancorp DE’s holdings in Hims & Hers Health were worth $47,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Crewe Advisors LLC bought a new stake in Hims & Hers Health in the fourth quarter valued at $28,000. Raleigh Capital Management Inc. boosted its holdings in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in Hims & Hers Health in the fourth quarter valued at $48,000. GAMMA Investing LLC boosted its holdings in Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after acquiring an additional 2,152 shares in the last quarter. Finally, Principal Securities Inc. boosted its holdings in Hims & Hers Health by 48.2% in the fourth quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after acquiring an additional 1,002 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 36,460 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the completion of the transaction, the chief executive officer now directly owns 27,918 shares in the company, valued at approximately $756,298.62. The trade was a 56.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Soleil Boughton sold 268,932 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00. Following the transaction, the insider now owns 169,803 shares of the company’s stock, valued at approximately $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,042,006 shares of company stock worth $36,830,024. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Stock Down 9.3 %

NYSE HIMS opened at $31.46 on Wednesday. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The firm has a market capitalization of $6.99 billion, a P/E ratio of 71.49 and a beta of 1.37. The company has a 50-day moving average price of $38.72 and a 200-day moving average price of $28.49.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on HIMS shares. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Citigroup restated a “sell” rating and set a $27.00 target price on shares of Hims & Hers Health in a report on Thursday, March 6th. Truist Financial boosted their target price on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a report on Wednesday, February 26th. Piper Sandler boosted their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. Finally, BTIG Research initiated coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.